1. Conformational studies on beta-amyloid protein carboxy-terminal region (residues 34-42): strategic use of amide backbone protection as a structural probe
M Quibell, T Johnson, W G Turnell Biomed Pept Proteins Nucleic Acids. 1994;1(1):3-12.
Analogues of beta-amyloid (32-42) peptide, containing N-(2-hydroxy-4-methoxybenzyl) (Hmb) amide backbone substitutions at various positions have been prepared using fluoren-9-ylmethoxycarbonyl (Fmoc)-polyamide based solid phase peptide synthesis. On-line N alpha-Fmoc deprotection monitoring during assembly exhibited hindered release in the native and beta A(34-42, (Hmb)Gly38) analogue syntheses. No such hindrance was observed during the synthesis of beta A(34-42, (Hmb)Gly37) nor beta A(34-42, (Hmb)Val36). However, the latter contained an exceptionally slow coupling reaction. Cleaved peptides were analysed for solubility in a variety of solvents and insoluble pellets tested for congophilic staining. X-ray analysis of Fmoc (and H-) beta A(34-42) and the corresponding (Hmb)Gly38 analogues as dimethylformamide swollen gels gave very similar structures. Secondary structure prediction and model-building of ordered arrays, compatible with our results, suggest that beta A(34-42) forms a beta-hairpin structure, with the reverse turn at Val36-Gly37-Gly38-Val39 both in solution and on the resin during synthesis.
2. Solution conformations and aggregational properties of synthetic amyloid beta-peptides of Alzheimer's disease. Analysis of circular dichroism spectra
C J Barrow, A Yasuda, P T Kenny, M G Zagorski J Mol Biol. 1992 Jun 20;225(4):1075-93. doi: 10.1016/0022-2836(92)90106-t.
The A4 or beta-peptide (39 to 43 amino acid residues) is the principal proteinaceous component of amyloid deposits in Alzheimer's disease. Using circular dichroism (c.d.), we have studied the secondary structures and aggregational properties in solution of 4 synthetic amyloid beta-peptides: beta-(1-28), beta-(1-39), beta-(1-42) and beta-(29-42). The natural components of cerebrovascular deposits and extracellular amyloid plaques are beta-(1-39) and beta-(1-42), while beta-(1-28) and beta-(29-42) are unnatural fragments. The beta-(1-28), beta-(1-39) and beta-(1-42) peptides adopt mixtures of beta-sheet, alpha-helix and random coil structures, with the relative proportions of each secondary structure being strongly dependent upon the solution conditions. In aqueous solution, beta-sheet structure is favored for the beta-(1-39) and beta-(1-42) peptides, while in aqueous solution containing trifluoroethanol (TFE) or hexafluoroisopropanol (HFIP), alpha-helical structure is favored for all 3 peptides. The alpha-helical structure unfolds with increasing temperature and is favored at pH 1 to 4 and pH 7 to 10; the beta-sheet conformation is temperature insensitive and is favored at pH 4 to 7. Peptide concentration studies showed that the beta-sheet conformation is oligomeric (intermolecular), whereas the alpha-helical conformation is monomeric (intramolecular). The rate of aggregation to the oligomeric beta-sheet structure (alpha-helix----random coil----beta-sheet) is also dependent upon the solution conditions such as the pH and peptide concentration; maximum beta-sheet formation occurs at pH 5.4. These results suggest that beta-peptide is not an intrinsically insoluble peptide. Thus, solution abnormalities, together with localized high peptide concentrations, which may occur in Alzheimer's disease, may contribute to the formation of amyloid plaques. The hydrophobic beta-(29-42) peptide adopts exclusively an intermolecular beta-sheet conformation in aqueous solution despite changes in temperature or pH. Therefore, this segment may be the first region of the beta-peptide to aggregate and may direct the folding of the complete beta-peptide to produce the beta-pleated sheet structure found in amyloid deposits. Differences between the solution conformations of the beta-(1-39) and beta-(1-42) peptides suggests that the last 3 C-terminal amino acids are crucial to amyloid deposition.
3. On the use of N-dicyclopropylmethyl aspartyl-glycine synthone for backbone amide protection
René Röder, Petra Henklein, Hardy Weisshoff, Clemens Mügge, Michael Pätzel, Ulrich Schubert, Louis A Carpino, Peter Henklein J Pept Sci. 2010 Jan;16(1):65-70. doi: 10.1002/psc.1196.
To prevent aspartimide formation and related side products in Asp-Xaa, particularly Asp-Gly-containing peptides, usually the 2-hydroxy-4-methoxybenzyl (Hmb) backbone amide protection is applied for peptide synthesis according to the Fmoc-protocols. In the present study, the usefulness of the recently proposed acid-labile dicyclopropylmethyl (Dcpm) protectant was analyzed. Despite the significant steric hindrance of this bulky group, N-terminal H-(Dcpm)Gly-peptides are quantitatively acylated by potent acylating agents, and alternatively the dipeptide Fmoc-Asp(OtBu)-(Dcpm)Gly-OH derivative can be used as a building block. In contrast to the Hmb group, Dcpm is inert toward acylations, but is readily removed in the acid deprotection and resin-cleavage step.
